Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.43
- Piotroski Score 3.00
- Grade Buy
- Symbol (GERN)
- Company Geron Corporation
- Price $4.07
- Changes Percentage (1.24%)
- Change $0.05
- Day Low $3.96
- Day High $4.11
- Year High $5.34
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $8.00
- Low Stock Price Target $4.50
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.34
- Trailing P/E Ratio -13.5
- Forward P/E Ratio -13.5
- P/E Growth -13.5
- Net Income $-184,127,000
Income Statement
Quarterly
Annual
Latest News of GERN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Move Over Nvidia and Palantir, This AI Juggernaut Is Up 628% Year to Date. Can the Stock's Momentum Continue?
AppLovin emerged as the top AI stock in 2024 with a 628% surge in share price post Q3 results. Revenue soared by 39% driven by Axon 2 AI technology. The company displayed strong operating leverage and...
By Yahoo! Finance | 1 week ago -
Geron (GERN) Q3 2024 Earnings Call Transcript
Geron recently had a transformative year with the FDA approval and commercial launch of Rytelo, a telomerase inhibitor. Achieving $28.2 million in net product revenue in the U.S. market exceeded expec...
By Yahoo! Finance | 2 weeks ago -
Warner's NBA Juggernaut on Last Legs as Zaslav Hypes DTC
Warner Bros. Discovery's third-quarter earnings show the significant impact of losing NBA rights on ad revenue. Despite upcoming changes, CEO Zaslav remains optimistic about future negotiations with C...
By Yahoo! Finance | 2 weeks ago
